| Followers | 65 |
| Posts | 27906 |
| Boards Moderated | 0 |
| Alias Born | 11/23/2016 |
Sunday, June 20, 2021 6:04:40 AM
Ladenburg Thalmann Healthcare Symposia on Rett Syndrome
From 07:00 Dr. Jeff Nuel briefly addresses seizures in Rett, which with age develop in over 80% of patients.
In the Q&A section at 27:40 Dr. Hagerman addresses seizures saying that "I did see a couple of individuals who had fewer seizures. There were some individuals who had no seizures in this study and that didn't change. I did not see anybody that had worsening of their seizures".
At about 30:00 Dr. Nuel tips in saying that "seizure burden drops as people age, seizures occur in many many people but the burden actually drops".
Now given the comments discusses are presumably based on the adult US Rett trial, I would not read too much into the seizures aspect.
Seizures, also discussed in the symposium video, are much more burdensome at a younger age but occur in fewer patients. So we have to see if the 12 week duration of the paediatric trial provides solid data on seizures.
In the only 7 weeks US Rett and the AU AVATAR studies, seizures is under other outcome measures.
Study of ANAVEX2-73 in Patients With Rett Syndrome
Whereas, in the 12 week paediatric Rett study seizures is a secondary outcome measure - so more important.
ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome (EXCELLENCE)
From 07:00 Dr. Jeff Nuel briefly addresses seizures in Rett, which with age develop in over 80% of patients.
In the Q&A section at 27:40 Dr. Hagerman addresses seizures saying that "I did see a couple of individuals who had fewer seizures. There were some individuals who had no seizures in this study and that didn't change. I did not see anybody that had worsening of their seizures".
At about 30:00 Dr. Nuel tips in saying that "seizure burden drops as people age, seizures occur in many many people but the burden actually drops".
Now given the comments discusses are presumably based on the adult US Rett trial, I would not read too much into the seizures aspect.
Seizures, also discussed in the symposium video, are much more burdensome at a younger age but occur in fewer patients. So we have to see if the 12 week duration of the paediatric trial provides solid data on seizures.
In the only 7 weeks US Rett and the AU AVATAR studies, seizures is under other outcome measures.
Study of ANAVEX2-73 in Patients With Rett Syndrome
Seizure Frequency via seizure diary [ Time Frame: 7 weeks ]
Seizure Frequency via seizure diary
Whereas, in the 12 week paediatric Rett study seizures is a secondary outcome measure - so more important.
ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome (EXCELLENCE)
Seizure Frequency via seizure diary [ Time Frame: 12 weeks ]
Seizure Frequency via seizure diary
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
